An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial
Free-Photos / Pixabay

An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial

According to a story from globenewswire.com, the experimental drug somatrogon, which is being co-developed by Pfizer, Inc. and OPKO Health, Inc., was able to achieve its primary endpoint in a…

Continue Reading An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial